Buprenorphine

Extended-Release Naltrexone Injections Reduce Opioid Dependence

Extended-Release Naltrexone Injections Reduce Opioid Dependence

By

Compared with buprenorphine-naloxone, use of extended-release naltrexone maintained abstinence from heroin and other illicit substances at a similar rate.

Transdermal to Buccal Buprenorphine Transition

Transdermal to Buccal Buprenorphine Transition

By

Patients can be transitioned from transdermal to buccal formulations of buprenorphine within 12 hours of patch removal using the recommended buccal formulation titration doses and schedule.

Opioid Dependence Prevention Treatments Compared

Opioid Dependence Prevention Treatments Compared

By

Significantly less heroin cravings were reported in the extended-release naltrexone group and treatment satisfaction was also reported higher in this group compared to the buprenorphine-naloxone group.

FDA's Strategies for Managing Patients Taking CNS Depressants and Opioids

FDA's Strategies for Managing Patients Taking CNS Depressants and Opioids

By

The FDA has recently issued a report advising against the use of buprenorphine and methadone medications in patients taking benzodiazepines and/or other central nervous system depressants.

Tramadol Effective on Opioid Withdrawal Symptoms

Tramadol Effective on Opioid Withdrawal Symptoms

By

The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.

Buprenorphine Injections Effective on Opioid-Associated Euphoria and Withdrawal

Buprenorphine Injections Effective on Opioid-Associated Euphoria and Withdrawal

By

Once-weekly subcutaneous buprenorphine injections block the euphoric effects of opioids and suppress opioid withdrawal in patients with opioid use disorder.

Buprenorphine and Naltrexone Underprescribed for Youth With Opioid Use Disorder

Buprenorphine and Naltrexone Underprescribed for Youth With Opioid Use Disorder

By

Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.

Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use Disorder

Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use Disorder

By

Patients receiving buprenorphine maintenance therapy for their opioid use disorder may have impaired sleep, despite their reports of improved quality and duration of sleep.

Is Opioid-Induced Hyperalgesia Lessened by Switching to Buprenorphine?

Is Opioid-Induced Hyperalgesia Lessened by Switching to Buprenorphine?

By

Changes in several measures of pain in patients suspected of opioid-induced hyperalgesia were observed after transitioning from opioids to buprenorphine.

Substance Use Disorders: Treatment Recommendations

Substance Use Disorders: Treatment Recommendations

By

Substance Use Disorder is a chronic medical condition, and should be treated like one.

Teens Exposed to Prescription Opioids at Risk for Serious Outcomes

Teens Exposed to Prescription Opioids at Risk for Serious Outcomes

Teenagers with prescription opioid exposures are more likely to have health care facility admission and serious medical outcomes than younger children.

Prescription Opioid Crisis: Public Health Response in Pennsylvania

Prescription Opioid Crisis: Public Health Response in Pennsylvania

By

Pennsylvania has adopted a multipronged approach to address the opioid crisis.

Emergency Department-Initiated Buprenorphine/Naloxone Beneficial When Prolonged

Emergency Department-Initiated Buprenorphine/Naloxone Beneficial When Prolonged

By

Buprenorphine/naloxone treatment initiated in the emergency department and prolonged for 10 weeks in primary care improved treatment engagement and reduced opioid use compared with referral or brief intervention.

Buprenorphine Effective in ER Patients With Opioid Addiction

Buprenorphine Effective in ER Patients With Opioid Addiction

Patients addicted to opioids treated in a hospital emergency department do better when they receive medication to reduce opioid cravings.

Naltrexone vs Buprenorphine to Treat Opioid Dependence

Naltrexone vs Buprenorphine to Treat Opioid Dependence

By

An 8-day detoxification process using low-dose oral naltrexone showed superior efficacy to the standard 15-day approach that uses an agonist taper leading to induction with extended-release naltrexone

New Prescribing Information Released for Hundreds of FDA-Approved Opioids

New Prescribing Information Released for Hundreds of FDA-Approved Opioids

Throughout 2016, the FDA has announced requirements for manufacturers to create new product labeling information for a variety of opioid medications.

3 Noteworthy Initiatives To Address the Opioid Epidemic

3 Noteworthy Initiatives To Address the Opioid Epidemic

By

The initiatives include guidelines and recommendations for CRNAs, physicians, and policymakers.

The Consequences of Limiting Physician Capacity to Rx Buprenorphine for Opioid Use Disorder

The Consequences of Limiting Physician Capacity to Rx Buprenorphine for Opioid Use Disorder

By

The researchers found that novice prescribers cited insufficient access to substance abuse counseling for patients, as well as insufficient access to more experienced prescribers, as reasons for not treating more patients.

A Pain Clinician's Perspective on the Comprehensive Addiction and Recovery Act

A Pain Clinician's Perspective on the Comprehensive Addiction and Recovery Act

By

There is a lot of opportunity to improve on what can be offered to patients.

Effectiveness of Subdermal Buprenorphine Implants in Maintaining Opioid Abstinence

Effectiveness of Subdermal Buprenorphine Implants in Maintaining Opioid Abstinence

By

Buprenorphine implants could help improve relapse prevention in patients who are currently maintaining abstinence with sublingual buprenorphine

Buprenorphine May Help Alleviate Diabetic Peripheral Neuropathic Pain

Buprenorphine May Help Alleviate Diabetic Peripheral Neuropathic Pain

When tolerated, buprenorphine is effective for diabetic peripheral neuropathic pain

FDA Approves Implantable Device for Steady Release of Buprenorphine

FDA Approves Implantable Device for Steady Release of Buprenorphine

By

Improved delivery method for buprenorphine

Sign Up for Free e-Newsletters